


PHARMACEUTICAL 2022

AMERICAN BIO MEDICA CORP Rank 257 of 475





PHARMACEUTICAL 2022

AMERICAN BIO MEDICA CORP Rank 257 of 475

The relative strengths and weaknesses of AMERICAN BIO MEDICA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMERICAN BIO MEDICA CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 430% points. The greatest weakness of AMERICAN BIO MEDICA CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 258% points.

The company's Economic Capital Ratio, given in the ranking table, is -124%, being 153% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	1,340
Cost of Goods Sold	1,670
Intangible Assets	0
Liabilities, Current	2,824
Liabilities, Non-Current	3.0
Other Assets	26
Other Compr. Net Income	0
Other Expenses	306
Other Liabilities	0
Other Net Income	718
Property and Equipment	517
Research and Development	85
Revenues	2,218
Selling, General and Administrative Expense	1,338

Output Variable	Value in 1000 USD
Assets	1,883
Liabilities	2,827
Expenses	3,399
Stockholders Equity	-944
Net Income	-463
Comprehensive Net Income	-463
Economic Capital Ratio	-124%